Gedea Biotech raises 1.5 MEUR (16.5 MSEK) in oversubscribed rights issue as registration CL3-2 trial begins
Gedea Biotech raises 1.5 MEUR (16.5 MSEK) in oversubscribed rights issue as registration CL3-2 trial begins Lund, Sweden, November 15, 2023: Gedea Biotech today announced that it has raised 1.5 MEUR (16,5 MSEK) to initiate and accelerate clinical trial activities supporting pHyph™ applicable for…
Gedea Biotech receives approval to initiate the pivotal NEFERTITI-2 clinical study documenting the performance of pHyph for treatment of bacterial vaginosis
This pivotal study aims to confirm the safety and efficacy of pHyph in treating and preventing BV recurrence Patient recruitment will now be initiated and 5 Swedish clinics are planned to attend Previous studies in BV have demonstrated pHyph to have a BV cure rate in line with antibiotics on the…